nVerses Capital LLC Takes $379,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

nVerses Capital LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,600 shares of the medical research company’s stock, valued at approximately $379,000.

Several other large investors also recently made changes to their positions in the stock. First Foundation Advisors increased its position in shares of IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after acquiring an additional 43 shares in the last quarter. Team Hewins LLC boosted its position in IQVIA by 5.0% during the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock worth $246,000 after acquiring an additional 46 shares during the last quarter. Invera Wealth Advisors LLC grew its stake in shares of IQVIA by 0.3% during the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after acquiring an additional 46 shares in the last quarter. Covestor Ltd raised its holdings in shares of IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in shares of IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after purchasing an additional 48 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Evercore ISI lowered their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Robert W. Baird upped their target price on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. UBS Group raised their price target on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Truist Financial dropped their price objective on IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Barclays decreased their target price on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $267.87.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by insiders.

IQVIA Trading Up 0.4 %

Shares of IQV stock opened at $233.89 on Friday. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a market capitalization of $42.61 billion, a PE ratio of 31.95, a price-to-earnings-growth ratio of 2.18 and a beta of 1.49. The firm has a 50 day moving average price of $239.09 and a two-hundred day moving average price of $231.35. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.22 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.